Novartis

Podcasts

Novartis, company culture and COVID-19: the pharmaphorum pod...

Novartis’ Steven Baert joined the pharmaphorum podcast for episode 22 to discuss how COVID-19 will change the face of company culture, now and in the future.

News

UCB’s IL-17 latecomer bimekizumab beats Cosentyx in psoriasi...

Belgian biopharma company UCB is bringing up the rear of the IL-17 inhibitor category with its bimekizumab drug, so is celebrating new late-stage data showing superiority to th

News

Novartis takes $485m hit after axing eczema drug from pipeli...

Novartis has axed development of its mid-stage eczema drug ZPL389, taking a $485 million hit in the process.

News

Pandemic hits sales at Novartis after strong launch for SMA ...

The COVID-19 pandemic has bit into sales at Novartis, the big Swiss pharma said in second quarter results, after orders fell back following a period of stockpiling earlier in the year.

News

Biogen plans trial of Spinraza in patients not responding to...

Biogen is planning to trial its Spinraza spinal muscular atrophy (SMA) drug in patients who have not responded properly to Novartis' gene therapy Zolgensma, combining the two ultra-expensiv

News

Doctor Checking Skin Of Patient With Magnifying Glass

Lilly’s mirikizumab tops Novartis’ blockbuster Cosentyx in p...

Eli Lilly is a latecomer in the new generation of biologic therapies for psoriasis with its mirikizumab candidate, but a win in a head-to-head trial against Novartis’ big-selli

Novartis, company culture and COVID-19: the pharmaphorum pod...

UCB’s IL-17 latecomer bimekizumab beats Cosentyx in psoriasi...

Novartis takes $485m hit after axing eczema drug from pipeli...

Pandemic hits sales at Novartis after strong launch for SMA ...

Biogen plans trial of Spinraza in patients not responding to...

Lilly’s mirikizumab tops Novartis’ blockbuster Cosentyx in p...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Novartis

Editor's Picks